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Context
Bronchiolitis is an acute, lower respiratory tract 
disease of viral aetiology that affects infants below 
2 years of age [1]. Bronchiolitis is common. One 
in five children have at least one healthcare visit 
related to bronchiolitis during infancy and it is a 
major cause of hospitalisation, accounting for 18% 
of all hospitalisations in the USA in children younger 
than 1 year [2]. The diagnosis is clinical and based 
on viral respiratory infection symptoms and signs 
such as tachypnoea, wheeze, crackles, rhonchi 
and respiratory distress [3]. There are no effective 
medical therapies for bronchiolitis so treatment is 
based on hydration and respiratory supportive care 
when necessary [3]. The use of high-flow oxygen 
through nasal cannula as respiratory support in 
infants with bronchiolitis has increased in recent 
years [4]. It provides a high flow of humidified air 
warmed to body temperature with an adjustable 
fraction of oxygen, and is usually well tolerated by 
infants. It may improve oxygenation and breathing 
effort by producing a positive pressure at the end 
of the expiration [5]. Franklin et al. [6] examined 
treatment failure resulting in escalation of care in 
infants with bronchiolitis and hypoxaemia who 
were treated in emergency departments or general 
paediatric wards with either high-flow oxygen 
or standard therapy with supplemental oxygen 
through a nasal cannula.
Methods
This multicentre randomised controlled trial was 
conducted in 17 Australian and New Zealand 
hospitals; eight of the hospitals had an on-site 
intensive care unit (ICU). Infants younger than 
12 months presenting with signs of bronchiolitis 
and needing supplemental oxygen to keep oxygen 
saturation above 92% or 94%, depending upon 
institutional practice, were included. Infants who 
needed oxygen therapy for any reason other than 
suspected bronchiolitis were excluded. Eligible 
infants were randomised to receive either standard-
therapy oxygen through a nasal cannula up to a 
maximum flow of 2 L·min−1, or high-flow therapy 
with humidified air with variable oxygen through 
a nasal cannula at a rate of 2 L·min−1 per kilogram 
bodyweight. In the standard-therapy group, flow 
rate was adjusted, while in the high-flow group the 
inspiratory oxygen fraction (FIO2) was varied. In both 
groups this was done to maintain oxygen saturation 
in the range of 92–98% (six hospitals) or 94–98% 
(11 hospitals). Children were randomised using a 
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computer-generated randomisation sequence with 
a block size of 10, stratified by hospital. Allocation 
was concealed but treatment was not blinded. The 
primary outcome was treatment failure resulting 
in an escalation of care. A conclusion of treatment 
failure was reached by a clinician if at least three 
of four criteria were met: 1) heart rate remained 
unchanged or increased since admission; 2) 
respiratory rate remained unchanged or increased 
since admission; 3) oxygen requirement in the 
high-flow group exceeded a FIO2 of at least 0.4 
to maintain an oxygen-saturation level of at least 
92% or 94%, depending on hospital threshold, or 
the requirement for supplemental oxygen in the 
standard-therapy group exceeded 2 L·min−1 to 
achieve the same oxygen-saturation threshold; 
4) the hospital internal early-warning tool (a 
standardised set of physiological and clinical 
factors) indicated medical review and escalation 
of care. Clinicians could also escalate care if they 
considered it appropriate for other clinical reasons 
apart from the four explicit criteria. Escalation of 
treatment was defined as an increase in respiratory 
support. Infants in the standard-therapy group 
who required escalation of care were changed to 
high-flow oxygen therapy and infants in the high-
flow group were transferred to an ICU. Secondary 
outcomes included the proportion of children 
transferred to an ICU; intubation; durations of 
hospital stay, ICU stay and oxygen therapy; and 
adverse events.
Main results
Between October 2013 and August 2016, 2217 
infants were eligible for inclusion, 1638 (74%) 
underwent randomisation, and 1472 (90% of 
those randomised) were included in the analysis. 
Treatment failure leading to escalation of care 
occurred more often in the standard-therapy 
group (167 out of 733, 23%) than in the high-
flow therapy group (87 out of 739, 12%) with a 
risk difference of 11% (95% CI 7–15%). Escalation 
of care was influenced by whether the hospital 
had an on-site ICU. In hospitals without an on-site 
ICU, care was escalated in 69 out of 247 infants 
(28%) in the standard-therapy group and 20 out 
of 270 (7%) in the high-flow group. In hospitals 
with an on-site ICU, care was escalated in 98 out 
of 486 infants (20%) in the standard-therapy 
group and 67 out of 469 (14%) in the high-flow 
group. Restricting analysis to children meeting 
at least three of the four criteria, treatment 
failure remained lower in the high-flow group, 
in which 53 out of 739 (7%) infants experienced 
treatment failure, in comparison with 115 out of 
733 (16%) in the standard-therapy group. There 
was no difference between the high-flow and 
the standard-therapy group regarding any of the 
secondary outcomes.
Commentary
This randomised controlled trial showed that 
treatment failure leading to escalation of care 
among children admitted for hypoxaemic 
bronchiolitis was lower among infants treated 
with high-flow oxygen supplementation than 
those treated with standard therapy. However, 
certain aspects of the study suggest that its results 
should be interpreted with caution. Comparison of 
the two groups is complicated by different main 
outcome definitions. In the high-flow oxygen group, 
the only way to escalate care was to transfer to 
ICU, whereas escalation of care in the standard-
therapy group was to cross over and start high-
flow oxygen. Clinicians might perceive switching 
infants from standard nasal cannula to high-flow 
oxygen as a smaller escalation step than transferring 
infants under high-flow oxygen therapy to the ICU, 
especially if high-flow therapy was already standard 
practice in their hospital. Were this true, it would 
increase escalation of care in the standard-therapy 
group compared to the high-flow group. Infants in 
the standard-therapy group had a lower respiratory 
rate at escalation than infants in the high-flow 
oxygen group, which suggests that perception was, 
to some extent, present. To address this problem, 
the authors performed a sensitivity analysis using 
the sample of patients that strictly met at least three 
out of four preset criteria for escalation of care. The 
analysis showed that escalation of care remained 
higher in the standard-therapy group, indicating 
that high-flow oxygen might really be better than 
standard therapy.
Presence or absence of an on-site ICU affected 
the risk of escalation of care in a different way 
in each treatment group. The risk difference in 
escalation of care was greater in hospitals without 
an on-site ICU than in those with an ICU. Possible 
reasons for this differ. ICU patient transfer could 
have been easier in hospitals with an on-site ICU. 
Also, clinicians might have greater confidence in 
waiting to escalate care from standard-therapy to 
high-flow oxygen if an ICU was present on-site. 
Therefore, it seems that mode of oxygenation 
did not alone influence escalation of care, but 
also presence of an on-site ICU. However, further 
sensitivity analyses including only infants that 
met at least three out of four preset criteria for 
escalation of care stratified by presence of an 
on-site ICU consistently favoured high-flow oxygen 
over standard therapy. In addition, Franklin 
et al. [6] did not mention whether there were any 
children who should have been escalated according 
to these criteria, but were not. Those children were 
not included in the sensitivity analysis and it is 
difficult to predict how this would have affected 
the results.
The comparatively higher cost of high-flow 
oxygen was not discussed by Franklin et al. [6]. 
Also, most of the infants in the standard-therapy 
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group did not require escalation of care, which 
indicates that most would not benefit from initial 
high-flow oxygen treatment. Additionally, no 
differences between the two groups were observed 
in any of the secondary outcomes, such as transfer 
to the ICU or intubation. In spite of the fact that 
escalation of care was experienced by fewer infants 
in the high-flow group, overall the cost–benefit 
balance would favour initiating treatment with 
traditional nasal cannula.
Most of the previous evidence for high-flow 
oxygen treatment of bronchiolitis comes from 
observational studies [7]. Among the few randomised 
controlled trials comparing high-flow oxygen to 
standard, low-flow oxygen therapy in infants with 
bronchiolitis [8, 9], this study by Franklin et al. [6] 
is the largest, and the most important.
Implications for practice
The escalation of care results of Franklin et al. 
[6] favour high-flow oxygen over standard nasal 
cannula. In the absence of other large randomised 
controlled trials, however, aspects of this study’s 
design and interpretation of its results, and the 
higher costs of high-flow therapy need to be 
considered before implementing high-flow 
therapy as initial therapy; previous commentators 
have also raised these points [10–13]. Further 
research is needed to establish the best moment 
to start high-flow oxygen therapy in hypoxaemic 
infants with bronchiolitis. In the meantime, 
clinicians should assess the individual situation 
of each patient before deciding to initiate high-
flow oxygen therapy.
Affiliations
Rebeca Mozun, Eva S.L. Pedersen, Cristina Ardura-Garcia
Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland.
Acknowledgements
We thank Chris Ritter (Institute of Social and Preventive Medicine, University of Bern, Bern, Switzerland) for his 
editorial contributions.
Conflict of interest
None declared. 
References
 1. Carroll KN, Gebretsadik T, Griffin MR, et al. Increasing burden 
and risk factors for bronchiolitis-related medical visits in infants 
enrolled in a state health care insurance plan. Pediatrics 2008; 
122: 58–64.
 2. Hasegawa K, Tsugawa Y, Brown DFM, et al. Trends in 
bronchiolitis hospitalizations in the United States, 2000–2009. 
Pediatrics 2013; 132: 28–36.
 3. Ralston SL, Liberthal AS, Meissner HC, et al. Clinical practice 
guideline: the diagnosis, management, and prevention of 
bronchiolitis. Pediatrics 2014; 134: e1474–e1502.
 4. Schlapbach LJ, Straney L, Gelbart B, et al. Burden of disease 
and change in practice in critically ill infants with bronchiolitis. 
Eur Respir J 2017; 49: 1601648.
 5. Sinha IP, McBride AKS, Smith R, et al. CPAP and high-flow 
nasal cannula oxygen in bronchiolitis. Chest 2015; 148: 
810–823.
 6. Franklin D, Babl FE, Schlapbach LJ, et al. A randomized trial of 
high-flow oxygen therapy in infants with bronchiolitis. N Engl 
J Med 2018; 378: 1121–1131.
 7. Florin TA, Plint AC, Zorc JJ. Viral bronchiolitis. Lancet 2017; 
389: 211–224.
 8. Kepreotes E, Whitehead B, Attia J, et al. High-flow warm 
humidified oxygen versus standard low-flow nasal cannula 
oxygen for moderate bronchiolitis (HFWHO RCT): an open, 
phase 4, randomised controlled trial. Lancet 2017; 389: 
930–939.
 9. Ergul AB, Caliskan E, Samsa H, et al. Using a high-flow nasal 
cannula provides superior results to OxyMask delivery in 
moderate to severe bronchiolitis: a randomized controlled 
study. Eur J Pediatr 2018; 177: 1299–1307.
 10. Meskill SD, Moore RH. High-flow oxygen therapy 
in infants with bronchiolitis. N Engl J Med 2018; 378: 
2444–2444.
 11. Modesto i Alapont V, Cusco MG, Medina A. High-flow 
oxygen therapy in infants with bronchiolitis. N Engl J Med 2018; 
378: 2444–2444.
 12. de Benedictis FM, Cogo P. High-flow oxygen therapy 
in infants with bronchiolitis. N Engl J Med 2018; 378: 
2444–2445.
 13. Linssen RS, van Woensel JB, Bont L. High-flow oxygen 
therapy in infants with bronchiolitis. N Engl J Med 2018; 378: 
2445–2446.
